Scorpius

Curia Appoints Steve Lavezoli as Vice President, Biologics

Retrieved on: 
Friday, February 23, 2024

ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26. Lavezoli will lead Curia’s biologics division, overseeing its discovery, development and manufacturing services.

Key Points: 
  • ALBANY, N.Y., Feb. 23, 2024 (GLOBE NEWSWIRE) -- Curia, a leading contract research, development and manufacturing organization, today announced it has appointed Steve Lavezoli as vice president of biologics effective Feb. 26.
  • Lavezoli will lead Curia’s biologics division, overseeing its discovery, development and manufacturing services.
  • “This is an exciting time for our biologics team, and we are pleased to have Steve on board,” said Curia CEO Philip Macnabb.
  • “Steve’s remarkable breadth of experience leading commercial operations for biologics development and manufacturing makes him a natural fit to lead our biologics efforts.

NightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating Officer

Retrieved on: 
Thursday, February 1, 2024

DURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the promotion of Joe Payne to President and Chief Operating Officer (COO) of its Scorpius BioManufacturing subsidiary.

Key Points: 
  • DURHAM, N.C., Feb. 01, 2024 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the promotion of Joe Payne to President and Chief Operating Officer (COO) of its Scorpius BioManufacturing subsidiary.
  • Payne joined Scorpius in 2023 as VP of Quality and Regulatory Affairs.
  • In his role as President and COO, Payne will oversee quality, manufacturing, process sciences, and commercial operations.
  • With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing.

NightHawk Receives Proceeds of $3.25 Million in Connection with Sale of Non-Core Intellectual Property and Issuance of a Low Interest Bearing Note

Retrieved on: 
Tuesday, January 30, 2024

Additionally, the Company received proceeds of $2.25 million from a note issued pursuant to the terms of the previously announced divestiture of non-core assets ( the “Note”).

Key Points: 
  • Additionally, the Company received proceeds of $2.25 million from a note issued pursuant to the terms of the previously announced divestiture of non-core assets ( the “Note”).
  • Jeff Wolf, CEO of NightHawk Biosciences, commented, “Receipt of these funds is particularly timely as it strengthens our balance sheet and provides us additional working capital to further accelerate our growth.
  • With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing.
  • This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.

NightHawk’s Scorpius BioManufacturing Subsidiary Commences Work on Preclinical Program for New Client

Retrieved on: 
Tuesday, January 16, 2024

The initial project value exceeds one million dollars, with the potential to exceed several million dollars over the next two years.

Key Points: 
  • The initial project value exceeds one million dollars, with the potential to exceed several million dollars over the next two years.
  • This award reflects our growing reputation in the industry, as well as our track record advancing early stage clinical programs.
  • Scorpius offers a broad array analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the-art facilities in San Antonio, TX.
  • With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing.

NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO

Retrieved on: 
Monday, January 8, 2024

The Company will continue to operate its CDMO within the Scorpius BioManufacturing subsidiary.

Key Points: 
  • The Company will continue to operate its CDMO within the Scorpius BioManufacturing subsidiary.
  • Jeff Wolf, CEO of Nighthawk, commented, “Our rebranding to Scorpius Holdings is a testament to our successful transition and the growth of our CDMO operations.
  • The industry faces a critical shortage of clinical-scale biologic manufacturing capacity, driven by increasing demand for large molecule CDMO services.
  • Our state-of-the-art facility in San Antonio, Texas ideally positions us to address this gap in CDMO manufacturing capacity and services.

NightHawk Biosciences Commences Work on Multi-Million-Dollar Development and Manufacturing Agreement For a Leading National University

Retrieved on: 
Wednesday, January 3, 2024

Jeff Wolf, CEO of NightHawk, commented, “We are honored to have been awarded this multi-million dollar contract by one of the foremost research universities in the United States.

Key Points: 
  • Jeff Wolf, CEO of NightHawk, commented, “We are honored to have been awarded this multi-million dollar contract by one of the foremost research universities in the United States.
  • Scorpius was selected due to its process development and large molecule manufacturing expertise, as well as its flexibility and dedication to customer service.
  • We are off to a strong start and look forward to expanding this relationship into additional programs in 2024 and beyond.
  • Scorpius offers a broad array analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state-of-the art facilities in San Antonio, TX.

Meteors, supermoons, a comet and more: your guide to the southern sky in 2024

Retrieved on: 
Tuesday, January 2, 2024

What exciting events will we see in the southern sky in 2024? Meteor showers, Saturn covered by the Moon, close approaches of bright planets to each other, supermoons – and, if we’re lucky, a comet visible to the naked eye. Even if you live in a city surrounded by light pollution, these are all worth looking out for. Here are some of the highlights.May – the Eta Aquarid meteors The first of the two main Southern Hemisphere meteor showers during the year is the Eta Aquariid or Eta Aquarid shower.

Key Points: 


What exciting events will we see in the southern sky in 2024? Meteor showers, Saturn covered by the Moon, close approaches of bright planets to each other, supermoons – and, if we’re lucky, a comet visible to the naked eye. Even if you live in a city surrounded by light pollution, these are all worth looking out for. Here are some of the highlights.

May – the Eta Aquarid meteors

  • The first of the two main Southern Hemisphere meteor showers during the year is the Eta Aquariid or Eta Aquarid shower.
  • It’s named after a star in the constellation of Aquarius, the Water Carrier, as the meteors appear to originate from there.

December – the Geminid meteors


The second of the two main meteor showers is the Geminid shower. This originates in the direction of the constellation of Gemini, the Twins. Unusually, they are associated not with a comet but with a rocky asteroid named Phaeton. In 2024, they are likely to be best seen early on the morning of Saturday 14 December. The peak time to view is during the short interval between the setting of the Moon and the start of dawn.

March, June and August – the planets

  • On the evening of Friday 22 March, the brightest planet Venus is less than the width of the Moon away from the ringed planet Saturn.
  • For people in the eastern part of Australia, the Moon covers the planet Saturn low in the eastern sky on the night of Thursday 27 June.
  • From Sydney, Saturn disappears at the bright edge of the Moon at 10:55pm and reappears at its dark edge at 11:41pm.


Another close approach is in the early morning of Thursday 15 August, when the red planet Mars is less than a Moon-width from the giant planet Jupiter.

September and October – supermoons

  • It’s best to look at moonrise, as an illusion in our brains makes the Moon appear larger when it’s near the horizon.
  • The supermoons in 2024 are on Wednesday 18 September and Thursday 17 October.

October – Comet C/2023 A3 (Tsuchinshan-ATLAS)

  • A comet with the impressive name of Comet C/2023 A3 (Tsuchinshan-ATLAS), discovered in January 2023, is approaching the Sun and Earth, and may become bright enough to be easily seen.
  • Read more:
    Astronomers just discovered a comet that could be brighter than most stars when we see it next year.
  • At a distance of 71 million kilometres, the comet will be closest to Earth on Sunday 13 October.

January and May – constellations


Not only these highlighted events can be seen in the sky. There are star pictures or constellations that still stand out in the sky of bright cities. Orion, the Hunter, is a favourite Southern Hemisphere summer constellation, high in the northern sky on January evenings. It consists of four bright stars in a rectangle with a line of three stars, representing Orion’s belt, in the middle.
According to Greek legend, Orion was a great hunter who vowed to kill all animals. To stop him carrying out his threat, one of the gods sent a scorpion to kill him. This ancient story with Scorpius, the Scorpion chasing Orion takes place above our heads each night.

  • In January, people who are up at around 3 am can see Scorpius rising in the east, while its quarry Orion is sinking in the west.
  • Alternatively, if you don’t like early mornings you can see the same scene on May evenings after dusk.


Nick Lomb received author fees from Powerhouse Publishing for writing the 2024 Australasian Sky Guide.

NightHawk Biosciences Announces Completion of Demonstration Run for a Top-Tier NIH and DTRA Funded Research University

Retrieved on: 
Thursday, December 21, 2023

DURHAM, N.C., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) (“NightHawk” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced its Scorpius BioManufacturing subsidiary (“Scorpius”) completed a demonstration run in the Company’s process development lab for a microbial vaccine program developed by a top-tier research university that is NIH and DTRA (Defense Threat Reduction Agency) funded.

Key Points: 
  • Jeff Wolf, CEO of NightHawk, commented, “This first phase of a multi-million-dollar project was particularly noteworthy, as we achieved a successful demonstration run following a prior failed attempt by a competitor CDMO.
  • The complexity of the project led this top-tier university to choose Scorpius, drawn by our more engaged management approach and accelerated development timeline.
  • The successful completion of this demonstration run showcases our team's dedication and expertise, and represents an important step in advancing our relationship with this nationally renowned university.
  • The next phase of this project will include scaling up to cGMP manufacturing to support a phase 1 infectious disease trial.

NightHawk Biosciences Announces Strategic Shift into a Pure-Play Large Molecule Biomanufacturing CDMO to Capitalize on Rapid Growth in Sales Pipeline along with Divestiture of Non-Core Assets

Retrieved on: 
Tuesday, December 12, 2023

DURHAM, N.C., Dec. 12, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK) today (“NightHawk” or the “Company”) announced its strategic shift into a pure-play biomanufacturing Contract Development & Manufacturing Organization (CDMO), as well as the divestiture of certain non-core assets, in order to focus on the growing sales within its Scorpius BioManufacturing subsidiary (“Scorpius”). The Company has booked contracts thus far in 2023, Scorpius’ first full year of operation, that are expected to generate over $20 million in revenue, a substantial portion of which will be recognized in 2024. To facilitate this strategic shift, the Company has divested its Elusys subsidiary and related assets, and has eliminated most of its R&D and associated expenses to focus its resources on growing and expanding Scorpius.

Key Points: 
  • The assets will be acquired by a private company established by Jeff Wolf, CEO of NightHawk, which will assume Elusys’ contracted financial commitments, currently estimated at over $40 million.
  • The royalties are subject to a mandatory minimum payment of $5 million during the first five years of the royalty term.
  • Scorpius booked $3 million in contracted sales in 2022, which has grown to over $20 million in contracted sales thus far in 2023.
  • With an experienced team and new, purpose-built U.S. facilities, Scorpius is dedicated to transparent collaboration and flexible, high-quality biologics biomanufacturing.

NightHawk Biosciences Provides Q3 2023 Business Update

Retrieved on: 
Monday, November 20, 2023

DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative therapies, today provided strategic, financial, and operational updates for the quarter ended September 30, 2023.

Key Points: 
  • DURHAM, N.C., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company specializing in the end-to-end development, manufacturing, and commercialization of innovative therapies, today provided strategic, financial, and operational updates for the quarter ended September 30, 2023.
  • As a result, we are currently evaluating a variety of strategic options to maximize the potential of the business.
  • Selling, general and administrative expenses were $6.1 million and $4.8 million for the three months ended September 30, 2023 and 2022, respectively.
  • NightHawk Biosciences leverages its integrated ecosystem of subsidiaries to streamline the advancement of novel therapies, breaking through barriers that prolong traditional drug development.